Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.
暂无分享,去创建一个
M. J. van de Vijver | J. Schellens | M. Vijver | A. Schinkel | G. Scheffer | R. Scheper | M. Maliepaard | A H Schinkel | R J Scheper | A. Pijnenborg | M. A. van Gastelen | I. Faneyte | G L Scheffer | M Maliepaard | J H Schellens | I F Faneyte | A C Pijnenborg | M A van Gastelen | M J van De Vijver | Margôt A. van Gastelen | Jan H.M. Schellens | George L. Scheffer | Marc Maliepaard | Ian F. Faneyte | Margôt A. van Gastelen | Adriana C. L. M. Pijnenborg | Marc J. van de Vijver
[1] J. Schellens,et al. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. , 2000, Journal of the National Cancer Institute.
[2] M. Kool,et al. Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. , 2000, Cancer research.
[3] J. Schellens,et al. Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. , 2000, Cancer research.
[4] D D Breimer,et al. Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. , 2000, The Journal of clinical investigation.
[5] D. Hipfner,et al. Structural, mechanistic and clinical aspects of MRP1. , 1999, Biochimica et biophysica acta.
[6] T. Litman,et al. Reversal of resistance by GF120918 in cell lines expressing the ABC half-transporter, MXR. , 1999, Cancer letters.
[7] J. Schellens,et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. , 1999, Cancer research.
[8] J. Wijnholds,et al. The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. , 1999, Cancer research.
[9] G. Peters,et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[10] A. Sartorelli,et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[11] M Dietel,et al. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. , 1999, Journal of the National Cancer Institute.
[12] W. Dalton,et al. Multiple mechanisms confer drug resistance to mitoxantrone in the human 8226 myeloma cell line. , 1999, Cancer research.
[13] T. Litman,et al. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. , 1999, Cancer research.
[14] L. Doyle,et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[15] Vincenzo,et al. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. , 1998, Cancer research.
[16] Der,et al. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[17] J. Schellens,et al. Co-administration of cyclosporin enables oral therapy with paclitaxel , 1998, The Lancet.
[18] P. Bosma,et al. Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[19] L. V. van't Veer,et al. A Method to Monitor mRNA Levels in Human Breast Tumor Cells Obtained by Fine‐needle Aspiration , 1997, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[20] M. Kool,et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.
[21] A. Schinkel,et al. The physiological function of drug-transporting P-glycoproteins. , 1997, Seminars in cancer biology.
[22] M. Kool,et al. Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR? , 1997, Seminars in cancer biology.
[23] J. Beijnen,et al. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[24] S. Withoff,et al. Differential expression of DNA topoisomerase II alpha and -beta in P-gp and MRP-negative VM26, mAMSA and mitoxantrone-resistant sublines of the human SCLC cell line GLC4. , 1996, British Journal of Cancer.
[25] Piet Borst,et al. MDR1 P-Glycoprotein Is a Lipid Translocase of Broad Specificity, While MDR3 P-Glycoprotein Specifically Translocates Phosphatidylcholine , 1996, Cell.
[26] J. Verweij,et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. , 1996, British Journal of Cancer.
[27] M. Flens,et al. Tissue distribution of the multidrug resistance protein. , 1996, The American journal of pathology.
[28] C. Meijer,et al. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. , 1994, Cancer research.
[29] P. Ternes,et al. An improved strategy and a useful housekeeping gene for RNA analysis from formalin-fixed, paraffin-embedded tissues by PCR. , 1993, BioTechniques.
[30] J. Trent,et al. Different mechanisms of decreased drug accumulation in doxorubicin and mitoxantrone resistant variants of the MCF7 human breast cancer cell line. , 1991, British Journal of Cancer.
[31] P. Meltzer,et al. Optimization of immunocytochemical P-glycoprotein assessment in multidrug-resistant plasma cell myeloma using three antibodies. , 1990, Laboratory investigation; a journal of technical methods and pathology.
[32] T. Grogan,et al. Immunohistochemical detection and quantitation of p-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation , 1989 .
[33] B. Slatko,et al. An Escherichia coli vector to express and purify foreign proteins by fusion to and separation from maltose-binding protein. , 1988, Gene.
[34] P. Romeo,et al. Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[35] Y. Gluzman. SV40-transformed simian cells support the replication of early SV40 mutants , 1981, Cell.